You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
First Genetics will market its F-Genetics NGS System and IVD assays to Russian laboratories for reproductive health testing and cancer diagnostics.
The company said it has signed a US distribution agreement for its COVID-19 test with an undisclosed strategic partner.
While down 6 percent year-over-year, the estimate beats analysts estimates of $1.5 billion and reflects a stronger-than-expected rebound in test volumes.
Vela Diagnostics said that the RT-PCR-based test has also received provisional authorization from the Health Sciences Authority in Singapore.
OpGen will promote the system for the enrichment of circulating endothelial cells from whole blood, which could be useful for COVID-19 research.
The firm said it will use the new capital to further develop cancer pathology workflows and create custom diagnostic and clinical trial solutions.
UCSF's test, developed with Mammoth Biosciences, uses CRISPR technology, while the tests from the Broad Institute and BioSewoom are PCR-based.
Analyzing both circulating tumor DNA and circulating tumor cells, investigators could classify patients into groups with significantly higher and lower recurrence risk.
Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.
The organizations requested a list of the names and contact information for individuals in each state overseeing the supply chain for testing supplies and PPE.